eMedicine Specialties > Psychiatry > Addiction

Nicotine Addiction

Author: Sat Sharma, MD, FRCPC, Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba; Site Director, Respiratory Medicine, St. Boniface General Hospital
Coauthor(s): Morley Lertzman, MD, FRCP(C), Professor, Department of Medicine, Section of Pulmonary Medicine, St Boniface Hospital, University of Manitoba, Canada
Contributor Information and Disclosures

Updated: Jun 11, 2009

Introduction

Background

Cigarette smoking is a major preventable cause of disease worldwide, and it is the major cause of premature death in North America. In 1912, Adler first suggested that inhalation of cigarette smoke might be a cause of lung cancer. Since then, knowledge about the adverse health effects of smoking has accumulated. The important causes of mortality are atherosclerotic vascular disease, cancer, and chronic obstructive pulmonary disease (COPD). Smoking also can contribute to other diseases, eg, histiocytosis X, respiratory bronchiolitis, obstructive sleep apnea, idiopathic pneumothorax, low birth weight, and perinatal mortality.

Tobacco addiction, the second-leading cause of death in the world, is a culprit for approximately 5 million deaths each year or 1 in 10 adult deaths. Currently, about 1.3 billion smokers live in the world; most (84%) live in developing countries.1 With the present smoking trends, tobacco will kill 10 million people each year by 2020.2 Through direct healthcare costs and loss of productivity from death and illness, tobacco will cost governments an estimated US $200 billion per year. A third of these costs will be borne by the developing countries. Many factors have led to increased global smoking rates. These include trade liberalization; direct foreign investment; global marketing; transnational tobacco advertising, promotion, and sponsorship; and international tobacco smuggling.

Research investigating why people smoke has shown that smoking behavior is multifaceted. Factors influencing smoking initiation differ from those of smoking behavior maintenance. Nicotine dependence, genetic factors, and psychosocial factors influence maintenance of smoking behavior.

Nicotine meets the criteria of a highly addictive drug. Nicotine is a potent psychoactive drug that induces euphoria, serves as a reinforcer of its use, and leads to nicotine withdrawal syndrome when it is absent. As an addictive drug, nicotine has 2 very potent issues: it is a stimulant and it is also a depressant. For example, one smoker talked too lovingly about her cigarettes who are called her "best friend." They got her going in the morning, and they chilled her out during the day.

Nicotine in cigarette smoke affects mood and performance and is the source of addiction to tobacco. While cigarette manufacturers have publicly denied that nicotine is an addictive drug, recent documents disclose that they have known and used the addictive properties of nicotine since the 1950s. Unfortunately, this misinformation led to the false belief that nicotine use is a habit and not an addiction.

All health care professionals should be aware of the risks of tobacco smoking, understand tobacco addiction, and assist patients with smoking cessation.

Pathophysiology

Nicotine releases hormone noted in the following paragraphs that act on various receptors in the brain. Nicotine use results in more efficient processing of information and reduction of fatigue. In addition, nicotine has a sedative action, reduces anxiety, and induces euphoria. Nicotine effects are related to absolute blood levels and to the rate of increase in drug concentration at receptors.

Nicotine stimulates the hypothalamic-pituitary axis; this, in turn, stimulates the endocrine system. Continually increasing dose levels of nicotine are necessary to maintain the stimulating effects. With regards to dependence, some experts rank nicotine ahead of alcohol, cocaine, and heroin. A teenager who smokes as few as 4 cigarettes might develop a lifelong addiction to nicotine.

Small rapid doses of nicotine produce alertness and arousal, as opposed to long drawn-out doses, which induce relaxation and sedation. Nicotine has a pronounced effect on the major stress hormones. Nicotine stimulates hypothalamic corticotropin-releasing factor (CRF), and it increases levels of endorphins, adrenocorticotropic hormone (ACTH), and arginine vasopressin in a dose-related manner. Corticosteroids also are released in proportion to plasma nicotine concentration.

Nicotine alters the bioavailability of dopamine and serotonin and causes a sharp increase in heart rate and blood pressure. Nicotine acts on brain reward mechanisms, indirectly through endogenous opioid activity and directly through dopamine pathways.

The association between depression and smoking is well established. A lifetime history of major depression is more than twice as common in people who smoke compared to people who do not smoke. A history of major depressive disorder is associated with a decreased ability to quit smoking and an increased likelihood of smoking relapse. Increased relapse rates of major depression after smoking cessation also have been described. In subjects with a history of major depression, smoking may be an attempt to decrease negative affect, and following a quit attempt, they are likely to experience greater symptoms of nicotine withdrawal compared to smokers without a history of depression. Therefore, in patients who are attempting to quit smoking, inquiring about present or past symptoms of depression and anxiety is advisable, and specific therapy may be indicated.

Frequency

United States

In 1965, 52% of men and 34% of women were cigarette smokers. Presently, the incidence of cigarette smoking has decreased to 28% and 24%, respectively. The incidence of smoking is highest in blacks, blue-collar workers, less-educated persons, and persons in the lower socioeconomic strata.

  • The trend is decreasing in more educated persons. Forty percent of men with less than 12 years of education, 35.9% of high school graduates, and 17.4% of college graduates smoke. Of women, 30.7% with less than 12 years of education, 29.6% of high school graduates, and 15.1% of college graduates smoke.
  • Economic status also is related to smoking behavior. Of men with an income of $10,000-20,000 per year, 36.3% smoke, as opposed to 23.2% of men who make $50,000 or more per year. Of women who had a family income of $20,000 or less per year, 29.8% smoke, as opposed to 19.5% who make $50,000 or more per year.
  • In 1983, a comparison was made between white-collar workers, of whom 27.9% smoked, and blue-collar workers, of whom 42.7% smoked.
  • Twenty-five percent of pregnant women who smoke quit during pregnancy; yet 80% resume smoking after childbirth.
  • Recent surveys show that 20% of teenage girls smoke, and 15% of teenage boys smoke.

International

Worldwide, approximately 1.1 billion people smoke. In China, more than 70% of men older than 25 years smoke. Smoking is more prevalent in developing countries and is continuing to increase. Prevalence of smoking in North America is decreasing, currently approximately 25% of North Americans smoke.

Mortality/Morbidity

The health consequences of this addiction are enormous. Tobacco smoking is responsible for 1 of every 5 deaths and is the most common cause of cancer-related deaths in the United States. Children smoke 1.1 billion packs of cigarettes yearly. This accounts for more than $200 billion in future health care costs.

Tobacco accounts for more than 85% of all deaths due to lung cancer. Approximately 10 million people in the United States have died from causes attributed to smoking since the Surgeon General's first report in 1964; 2 million of these were from lung cancer alone. Furthermore, tobacco also has been identified as the leading cause of emphysema, COPD, bronchitis, and heart disease.

  • Laryngeal cancer is uncommon; however, in 1988, it accounted for 1.1% of cancer-related deaths in men and 0.3% of cancer-related deaths in women. Oral cancer accounted for approximately 2.1% of male cancer-related deaths and 1.2% of female cancer-related deaths in 1988. Cigarette smoking and tobacco chewing are major causes of this disease. Esophageal cancer accounted for 2.6% of male cancer-related deaths and 1% of female cancer-related deaths. Approximately 50% of overall esophageal cancer mortality is due to cigarette smoking.
  • Bladder cancer accounted for 2.4% of male cancer-related deaths and 1.3% of female cancer-related deaths in 1988; approximately one third of these deaths were related to cigarette smoking. Pancreatic cancer accounted for approximately 5% of cancer-related deaths in 1990; one third of these deaths were associated with cigarette smoking. Kidney cancer accounted for 2.3% of male cancer-related deaths and 1.8% of female cancer-related deaths. Smoking has been established as an independent risk factor for uterine cervical cancer. Anal cancer in both heterosexual men and women also was due largely to cigarette smoking. Interactions between viral factors and tobacco exposure increase cancer risk.
  • Nonsmokers exposed to environmental tobacco smoke have a significantly higher risk of developing cancers and pulmonary diseases. Concentrations of toxins and carcinogens are higher in sidestream smoke. Children exposed to secondhand smoke develop a variety of respiratory disorders and morbidity.

Race

The smoking rate in the United States is higher among blacks than whites and is steadily increasing in Hispanics. In 1987, 39% of the black male population were smokers, compared to 30.5% of white men; 28% of black women were smokers, as opposed to 26.7% of white women. In addition, 30% of Hispanic men and 18% of Hispanic women were smokers.

Sex

In the United States, approximately 28% of men and 24% of women smoke.

Age

Studies reveal that the average age of first-time smokers is 14.5 years and the average age of daily smokers is 17.7 years. Approximately 20% of high school seniors smoke.

Clinical

History

  • Nicotine addiction is classified as nicotine use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). The criteria for this diagnosis include any 3 of the following within a 1-year time span:
    • Tolerance to nicotine with decreased effect and increasing dose to obtain same effect
    • Withdrawal symptoms after cessation
    • Smoking more than usual
    • Persistent desire to smoke despite efforts to decrease intake
    • Extensive time spent smoking or purchasing tobacco
    • Postponing work, social, or recreational events in order to smoke
    • Continuing to smoke despite health hazards
  • Nicotine withdrawal is classified as a nicotine-induced disorder according to the DSM-IV-TR. Symptoms include difficulty concentrating, nervousness, headaches, weight gain due to increased appetite, decreased heart rate, insomnia, irritability, and depression. These symptoms peak in the first few days but eventually disappear within a month.
  • Symptoms of nicotine toxicity, otherwise known as acute nicotine poisoning, include nausea, vomiting, salivation, pallor, abdominal pain, diarrhea, and cold sweat.
  • A previous history of depression, use of antidepressants in the past, and onset of depression during previous quit attempts should be obtained.

Physical

  • Physical effects of nicotine use include increased heart rate, accelerated blood pressure, and weight loss.
  • Physical effects of nicotine withdrawal and smoking cessation include weight gain due to increase in appetite, decreased heart rate, and improvement in the senses of taste and smell.
  • A complete mental status is indicated to rule out other forms of psychopathology.

More on Nicotine Addiction

Overview: Nicotine Addiction
Differential Diagnoses & Workup: Nicotine Addiction
Treatment & Medication: Nicotine Addiction
Follow-up: Nicotine Addiction
Multimedia: Nicotine Addiction
References

References

  1. Esson L, Leeder SR. The millennium development goals and tobacco control: an opportunity for global partnership. Geneva: World Health Organization (WHO); 2004.

  2. World Health Organization. Why is tobacco a public health priority? A Tobacco Free Initiative; 2005. Accessed March 30, 2006. [Full Text].

  3. US Preventive Services Task Force. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: US Preventive Services Task Force Reaffirmation Recommendation Statement. Ann Int Med. Apr 21 2009;150(8):551-555. [Full Text].

  4. Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care. Oct 2000;45(10):1196-9. [Medline].

  5. Henningfield JE, Fant RV, Buchhalter AR. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. Sep-Oct 2005;55(5):281-99; quiz 322-3, 325. [Medline].

  6. Stotts RC, Roberson PK, Hanna EY. A randomised clinical trial of nicotine patches for treatment of spit tobacco addiction among adolescents. Tob Control. Dec 2003;12 Suppl 4:IV11-5. [Medline].

  7. Etter JF, Huguelet P, Perneger TV, Cornuz J. Nicotine gum treatment before smoking cessation. Arch Intern Med. Jun 8 2009;169(11):1028-1034. [Full Text].

  8. [Guideline] U.S. Department of Health and Human Services. Public Health Service. Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008. [Full Text].

  9. Kornitzer M, Boutsen M, Dramaix M. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. Jan 1995;24(1):41-7. [Medline].

  10. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. Mar 4 1999;340(9):685-91. [Medline].

  11. Dale LC, Schroeder DR, Wolter TD. Weight change after smoking cessation using variable doses of transdermal nicotine replacement. J Gen Intern Med. Jan 1998;13(1):9-15. [Medline].

  12. Allen SS, Hatsukami D, Brintnell DM. Effect of nicotine replacement therapy on post-cessation weight gain and nutrient intake: a randomized controlled trial of postmenopausal female smokers. Addict Behav. Aug 2005;30(7):1273-80. [Medline].

  13. Benowitz NL. Sodium intake from smokeless tobacco. N Engl J Med. Sep 29 1988;319(13):873-4. [Medline].

  14. Benowitz NL, Jacob P 3rd. Nicotine metabolism in nonsmokers. Clin Pharmacol Ther. Oct 1990;48(4):473-4. [Medline].

  15. Bergen AW, Caporaso N. Cigarette smoking. J Natl Cancer Inst. Aug 18 1999;91(16):1365-75. [Medline].

  16. [Best Evidence] Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. Jan 24 2007;CD006103. [Medline].

  17. Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE. Jun 25 2008;3(6):e2547. [Medline].

  18. Croghan IT, Offord KP, Evans RW, et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc. Oct 1997;72(10):917-24. [Medline].

  19. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. Dec 3 1997;278(21):1759-66. [Medline].

  20. Dewar AL, Esson L, Entwistle C. Prior learning assessment. Putting experience to the test. Can Nurse. May 2002;98(5):28-31. [Medline].

  21. Giovino GA. The tobacco epidemic in the United States. Am J Prev Med. Dec 2007;33(6 Suppl):S318-26. [Medline].

  22. Goldstein MG, Niaura R, Willey-Lessne C, et al. Physicians counseling smokers. A population-based survey of patients' perceptions of health care provider-delivered smoking cessation interventions. Arch Intern Med. Jun 23 1997;157(12):1313-9. [Medline].

  23. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet. Jun 14 2008;371(9629):2027-38. [Medline].

  24. Henningfield JE, Burns DM, Dybing E. Guidance for research and testing to reduce tobacco toxicant exposure. Nicotine Tob Res. Dec 2005;7(6):821-6. [Medline].

  25. Hughes JR, Cummings KM, Hyland A. Ability of smokers to reduce their smoking and its association with future smoking cessation. Addiction. Jan 1999;94(1):109-14. [Medline].

  26. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA. Jan 6 1999;281(1):72-6. [Medline].

  27. Hughes JR, Stead LF, Lancaster T. Anxiolytics and antidepressants for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD000031. [Medline].

  28. Humble C, Croft J, Gerber A, et al. Passive smoking and 20-year cardiovascular disease mortality among nonsmoking wives, Evans County, Georgia. Am J Public Health. May 1990;80(5):599-601. [Medline].

  29. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. Oct 23 1997;337(17):1195-202. [Medline].

  30. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. Dec 12 1996;335(24):1792-8. [Medline].

  31. Mahmarian JJ, Moye LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. Jul 1997;30(1):125-30. [Medline].

  32. Manley M, Epps RP, Husten C, et al. Clinical interventions in tobacco control. A National Cancer Institute training program for physicians. JAMA. Dec 11 1991;266(22):3172-3. [Medline].

  33. Mason RJ, Buist AS, Fisher EB, et al. Cigarette smoking and health. Am Rev Respir Dis. Nov 1985;132(5):1133-6. [Medline].

  34. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. Feb 1996;109(2):438-45. [Medline].

  35. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. Mar 9 2000;342(10):681-9. [Medline].

  36. O'Hara P, Connett JE, Lee WW, et al. Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol. Nov 1 1998;148(9):821-30. [Medline].

  37. Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains--in our lifetime. Am J Prev Med. Dec 2007;33(6 Suppl):S340-8. [Medline].

  38. Richmond RL, Kehoe L, de Almeida Neto AC. Three year continuous abstinence in a smoking cessation study using the nicotine transdermal patch. Heart. Dec 1997;78(6):617-8. [Medline].

  39. [Best Evidence] Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. Jan 23 2008;CD000146. [Medline].

Further Reading

Keywords

smoking cessation, lung cancer, cigarettes, cigarette smoking, chronic obstructive pulmonary disease, COPD, emphysema, atherosclerotic vascular disease, atherosclerosis, nicotine addition, quitting smoking, tobacco addiction, lung disease

Contributor Information and Disclosures

Author

Sat Sharma, MD, FRCPC, Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba; Site Director, Respiratory Medicine, St. Boniface General Hospital
Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, Society of Critical Care Medicine, and World Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Morley Lertzman, MD, FRCP(C), Professor, Department of Medicine, Section of Pulmonary Medicine, St Boniface Hospital, University of Manitoba, Canada
Morley Lertzman, MD, FRCP(C) is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society
Disclosure: Nothing to disclose.

Medical Editor

Sarah C Aronson, MD, Associate Professor, Departments of Psychiatry and Medicine, Case Western Reserve School of Medicine/University Hospitals of Cleveland
Sarah C Aronson, MD is a member of the following medical societies: American Academy of Family Physicians, American Medical Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories
Eduardo Dunayevich, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.